Showing 13 to 24 of 158 results
FDA Clears Lumipulse Blood Test for Early Alzheimer's Detection
The FDA cleared Lumipulse, a blood test detecting Alzheimer's amyloid plaques in symptomatic adults over 55, improving early diagnosis and access to new treatments, potentially reducing reliance on expensive and invasive procedures.
FDA Clears Lumipulse Blood Test for Early Alzheimer's Detection
The FDA cleared Lumipulse, a blood test detecting Alzheimer's amyloid plaques in symptomatic adults over 55, improving early diagnosis and access to new treatments, potentially reducing reliance on expensive and invasive procedures.
Progress
44% Bias Score
FDA to Deploy Generative AI Agency-Wide by June 2025
The FDA announced plans to deploy generative AI enterprise-wide by June 2025, following a successful pilot program that demonstrated significant time savings in document review and scientific analysis, aiming to accelerate the review process for new therapies without compromising safety, privacy, or...
FDA to Deploy Generative AI Agency-Wide by June 2025
The FDA announced plans to deploy generative AI enterprise-wide by June 2025, following a successful pilot program that demonstrated significant time savings in document review and scientific analysis, aiming to accelerate the review process for new therapies without compromising safety, privacy, or...
Progress
44% Bias Score
FDA Ban on Compounded GLP-1 Drugs Restricts Access for Thousands
The FDA's ban on compounded GLP-1 medications, effective this week, will restrict access for thousands of patients who rely on these lower-cost alternatives for weight loss and diabetes, despite concerns about potential shortages and insurance coverage challenges.
FDA Ban on Compounded GLP-1 Drugs Restricts Access for Thousands
The FDA's ban on compounded GLP-1 medications, effective this week, will restrict access for thousands of patients who rely on these lower-cost alternatives for weight loss and diabetes, despite concerns about potential shortages and insurance coverage challenges.
Progress
60% Bias Score
FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns
The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.
FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns
The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.
Progress
56% Bias Score
FDA Expands COVID-19 Vaccine Warnings for Myocarditis Risk in Young Men
The FDA is expanding warning labels on Pfizer and Moderna's COVID-19 vaccines to include a higher risk of myocarditis and pericarditis in males aged 16-25, citing a rate of 38 cases per million doses compared to 8 per million in other groups, based on a study published last year and new agency data....
FDA Expands COVID-19 Vaccine Warnings for Myocarditis Risk in Young Men
The FDA is expanding warning labels on Pfizer and Moderna's COVID-19 vaccines to include a higher risk of myocarditis and pericarditis in males aged 16-25, citing a rate of 38 cases per million doses compared to 8 per million in other groups, based on a study published last year and new agency data....
Progress
64% Bias Score
FDA-Approved Blood Test Revolutionizes Alzheimer's Diagnosis in Greece
The FDA-approved Lumipulse blood test, now available at the Ionian University's laboratory in Greece, offers a highly accurate, non-invasive method for diagnosing Alzheimer's disease, impacting 35 million individuals globally and potentially accelerating treatment.
FDA-Approved Blood Test Revolutionizes Alzheimer's Diagnosis in Greece
The FDA-approved Lumipulse blood test, now available at the Ionian University's laboratory in Greece, offers a highly accurate, non-invasive method for diagnosing Alzheimer's disease, impacting 35 million individuals globally and potentially accelerating treatment.
Progress
16% Bias Score
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
Progress
40% Bias Score
FDA Mandates Updated Covid-19 Vaccine Warning Labels
The FDA mandates updated Covid-19 vaccine warning labels for Pfizer-BioNTech and Moderna, specifying a slightly increased risk of myocarditis/pericarditis in males aged 16-25 based on health insurance claims data analysis showing 38 cases per million doses, highlighting the importance of transparenc...
FDA Mandates Updated Covid-19 Vaccine Warning Labels
The FDA mandates updated Covid-19 vaccine warning labels for Pfizer-BioNTech and Moderna, specifying a slightly increased risk of myocarditis/pericarditis in males aged 16-25 based on health insurance claims data analysis showing 38 cases per million doses, highlighting the importance of transparenc...
Progress
48% Bias Score
Multistate Salmonella Outbreak Linked to Cucumbers
A multistate salmonella outbreak, impacting 26 individuals across 15 states (9 hospitalized), is linked to cucumbers from Bedner Growers Inc., distributed by Fresh Start Produce Inc., between April 29 and May 19, 2025; the FDA and CDC are investigating.
Multistate Salmonella Outbreak Linked to Cucumbers
A multistate salmonella outbreak, impacting 26 individuals across 15 states (9 hospitalized), is linked to cucumbers from Bedner Growers Inc., distributed by Fresh Start Produce Inc., between April 29 and May 19, 2025; the FDA and CDC are investigating.
Progress
32% Bias Score
COVID-19 Vaccine Approval Limited to High-Risk Groups
The Trump administration announced it will limit approval of seasonal COVID-19 shots to seniors and high-risk individuals, pending more data, causing concerns about access for those who want a fall booster, reversing the previous policy recommending annual shots for everyone over six months.
COVID-19 Vaccine Approval Limited to High-Risk Groups
The Trump administration announced it will limit approval of seasonal COVID-19 shots to seniors and high-risk individuals, pending more data, causing concerns about access for those who want a fall booster, reversing the previous policy recommending annual shots for everyone over six months.
Progress
48% Bias Score
FDA Limits Future COVID-19 Vaccine Access to Older Adults and Those with Underlying Conditions
The FDA announced it will restrict future COVID-19 vaccine access to people over 65 or with underlying health conditions, citing lack of benefit for healthy individuals and the cost of large trials; this affects an estimated 230 million Americans, aligning with policies in other countries.
FDA Limits Future COVID-19 Vaccine Access to Older Adults and Those with Underlying Conditions
The FDA announced it will restrict future COVID-19 vaccine access to people over 65 or with underlying health conditions, citing lack of benefit for healthy individuals and the cost of large trials; this affects an estimated 230 million Americans, aligning with policies in other countries.
Progress
44% Bias Score
FDA Shifts COVID-19 Vaccine Policy to Prioritize High-Risk Individuals
The FDA is shifting its annual COVID-19 vaccine approval policy to prioritize high-risk individuals (over 65 and those with increased risk factors) while demanding more robust data for low-risk individuals, aiming to rebuild public trust and align with international guidelines; this will affect vacc...
FDA Shifts COVID-19 Vaccine Policy to Prioritize High-Risk Individuals
The FDA is shifting its annual COVID-19 vaccine approval policy to prioritize high-risk individuals (over 65 and those with increased risk factors) while demanding more robust data for low-risk individuals, aiming to rebuild public trust and align with international guidelines; this will affect vacc...
Progress
48% Bias Score
Showing 13 to 24 of 158 results